Increasing the Effectiveness of Treatment of Intrahepatic Cholestasis Syndrome

Abstract

Despite the improvement of preventive and therapeutic diagnostic methods, liver diseases continue to be a common cause of complications and deaths. In recent years, a number of international and national recommendations have been published aimed at optimizing the pharmacotherapy of liver diseases. The introduction of patients with chronic liver diseases (CLD) with intrahepatic cholestasis syndromes requires significant material costs - this is not only payment for treatment, but also indirect costs with temporary and permanent disability of the patient. This fact necessitates the use by doctors of modern and effective methods for diagnosing the prevention and treatment of CLD.